Previous Statements by UTHR
» United Therapeutics Corporation Special Call
» United Therapeutics' CEO Discusses Q2 2011 Results - Earnings Call Transcript
» United Therapeutics Corporation Q4 2009 Earnings Call Transcript
We achieved over $200 million in revenue this quarter, which reflects the continued strength of our core business. I'm also pleased to report that our Board of Directors recently authorized a $300 million share repurchase program, which has already begun to return additional value to our shareholders. The combination of these 2 main points from our quarterly release is that United Therapeutics' growth story remains very strong, and we remain committed to sharing that value with our shareholders on a regular basis.I'd like to point out a couple of things that are, perhaps, not quite so clear from the black and white letters of the press release. The GAAP profitability has almost doubled from the third quarter of 2010 to the third quarter 2011 and also, for the 9 months of 2010 to 9 months of 2011. So that, certainly, is a very exciting dynamic indication of the strength of the core business. Now I think when you take a look at the reasons behind the growth, one has to take a look primarily at the fact that United Therapeutics is a company that is committed to doing the absolute best that can be done for the pulmonary hypertension community. In fact, with now over 6,000 patients on Adcirca, over 3,000 patients on Flolan -- I'm sorry, on Remodulin, excuse the slip, and over 2,000 patients on Tyvaso, United Therapeutics actually helps more American patients with pulmonary hypertension than any other company in the world. And that's something we're really excited about, because we formed our company 15 years ago specifically to help patients with pulmonary hypertension. Certainly, Adcirca has been a big part of our ability to reach out to more and more patients. Yet, even with the 6,000 patients we're helping on Adcirca, that's only about 20% of the diagnosed U.S. patients with pulmonary hypertension. And all of the data out there really supports the fact that there should be no patient with pulmonary hypertension who is not on a PDE-5 background therapy of which Adcirca is the most convenient, efficacious as any, as safe as any and the least expensive. So you really get 4 of a kind with Adcirca, and we certainly expect that growth to continue from its current 6,000 level up until we are hitting something close to the 30,000 patients in the U.S. with PAH who could all benefit with it.
Let's take a look at Tyvaso. Over 2,000 patients benefiting from that now, a true revolution in prostacyclin therapy. And what patients used to have to endure 24 hours a day, 365 days a year, they now just have 4 brief 1- to 2-minute inhalation session and achieve significant therapeutic benefit.We're really excited with the growth in Tyvaso revenues, which we've been sharing with you for the past few quarters, but the fact of the matter is, is that in terms of Class III patients, which is the label for Tyvaso, we are serving maybe about 20% of the patients. So we still have 4 steps of the way to go to achieve the peak revenue potential of Tyvaso among the pulmonary hypertension community. So again, a very, very exciting growth trajectory on Tyvaso. And finally, let's talk about Remodulin. Notwithstanding the fact that it has been on the market for 9 years, as the numbers for this quarter demonstrate, Remodulin continues to be a strong growth story. The reason for that is simply that physicians have achieved great comfort with Remodulin. And we, as a company, have gone to every possible length possible to make Remodulin as convenient and powerful for the patients as possible. Read the rest of this transcript for free on seekingalpha.com